Takeda ’s Dengue Vaccine Recommended by World Health Organization Advisory Group for Introduction in High Dengue Burden and Transmission Areas in Children Ages Six to 16 Years
Experts Reviewed Data from Qdenga’s Clinical Program Across 19 Phase 1, 2 and 3 Trials with More Than 28,000 Participants
WHO Will Consider the SAGE Recommendation and Provide Final Guidance on the Use of Qdenga in Public Vaccination...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
More News: Children | Clinical Trials | Dengue Fever | International Medicine & Public Health | Pharmaceuticals | Vaccines | WHO